Direct antivirals for the treatment of chronic hepatitis C virus infection. Experience in 106 patients.

Simple item page
dc.catalogadorjwg
dc.contributor.authorSoza Ried, Alejandro
dc.contributor.authorBenítez Gajardo, Carlos Esteban
dc.contributor.authorBarrera Álvarez, Francisco Benjamín
dc.contributor.authorMonrroy Bravo, Hugo Alfonso
dc.contributor.authorVargas Domínguez, José Ignacio
dc.contributor.authorArab Verdugo, Juan Pablo
dc.contributor.authorArrese Jiménez, Marco Antonio
dc.contributor.authorSarmiento, V.
dc.contributor.authorFuster, F.
dc.date.accessioned2024-01-16T14:18:31Z
dc.date.available2024-01-16T14:18:31Z
dc.date.issued2017
dc.description.abstractBackground: The availability of direct-acting antivirals (DAA) for the treatment of chronic hepatitis C virus (HCV) infection is just starting to expand in Chile. Aim: To report the initial experience of patients treated with DAA and their evolution after treatment. Material and Methods: Prospective cohort study, from June 2013 to August 2016 of patients treated with DAA for HCV in three clinical centers. The presence of cirrhosis, clinical and laboratory features; adverse events (AE) and post-treatment changes in liver function were evaluated. Sustained viral response at 12 weeks post-treatment (SVR12) was determined. Results: One hundred six patients aged 58 +/- 13 years, 54% males, were included. HCV genotype 1b was present in 88% and 47% had cirrhosis. Treatment regimens were asunaprevir + daclatasvir (DCV) in 17% of patients, paritaprevir / ritonavir / ombitasvir + dasabuvir in 33%, sofosbuvir (SOF) + DCV in 19%, and SOF + ledipasvir in 30%. Twenty five percent of patients used generic drugs. SVR12 was 92.1%, with no differences between generic and brand-name drugs. Serious AE were recorded in 22% of patients, being more common in those with cirrhosis (34% vs 11.5%, p < 0.01). At 12 weeks post-treatment follow-up, there was a decrease in aminotransferase values (p < 0.01), improvement in Child-Pugh score (5.9 vs. 5.5, p = 0.03) and decreased presence of ascites (p = 0.02). Conclusions: In our setting, DAA for HCV was highly effective and safe in non-cirrhotic patients. Hepatic function and inflammation improved at 12 weeks of follow-up. AE were common in patients with cirrhosis, suggesting that these patients should be treated by experienced teams. Generic drugs had similar effectiveness compared to originals.
dc.description.funderBasal
dc.fuente.origenHistorial Académico
dc.identifier.citationJose Ignacio Vargas, Juan Pablo Arab, Hugo Monrroy, Francisco Barrera, Carlos Benítez, Marco Arrese, Alejandro Soza. Direct antivirals for the treatment of chronic hepatitis C virus infection. Experience in 106 patients.. Revista Medica. 2017;145(10):1235-1242.
dc.identifier.doi10.4067/S0034-9887201700100123
dc.identifier.urihttps://scielo.conicyt.cl/scielo.php?script=sci_arttext&pid=S0034-98872017001001235&lng=en&nrm=iso&tlng=en
dc.identifier.urihttps://repositorio.uc.cl/handle/11534/80478
dc.identifier.wosidWOS:000429035100001
dc.information.autorucMedicina;Francisco Barrera;S/I;14816
dc.information.autorucEscuela de Medicina; Soza Ried Alejandro; 0000-0002-1136-9554; 461
dc.information.autorucEscuela de Medicina; Benitez Gajardo Carlos Esteban; ; 9202
dc.information.autorucEscuela de Medicina; Barrera Alvarez Francisco Benjamin; ; 1240448
dc.information.autorucEscuela de Medicina; Monrroy Bravo Hugo Alfonso; 0000-0002-4740-3945; 182401
dc.information.autorucEscuela de Medicina; Vargas Dominguez Jose Ignacio; 0000-0002-1547-2292; 120713
dc.information.autorucEscuela de Medicina; Arab Verdugo Juan Pablo; 0000-0002-8561-396X; 132745
dc.information.autorucEscuela de Medicina; Arrese Jimenez Marco Antonio; 0000-0002-0499-4191; 76095
dc.issue.numero10
dc.language.isoen
dc.nota.accesoContenido parcial
dc.pagina.final1242
dc.pagina.inicio1235
dc.revistaRevista Medica
dc.rightsacceso restringido
dc.subject.ods03 Good Health and Well-being
dc.subject.odspa03 Salud y bienestar
dc.titleDirect antivirals for the treatment of chronic hepatitis C virus infection. Experience in 106 patients.
dc.typeartículo
dc.volumen145
sipa.codpersvinculados14816
sipa.codpersvinculados461
sipa.codpersvinculados9202
sipa.codpersvinculados1240448
sipa.codpersvinculados182401
sipa.codpersvinculados120713
sipa.codpersvinculados132745
sipa.codpersvinculados76095
sipa.trazabilidadHistorial Académico;09-07-2021
sipa.trazabilidadORCID;2024-01-08
Files
Collections
Artículos de revistas